MA33742B1 - Co-cristaux de tramadol et de coxibs - Google Patents
Co-cristaux de tramadol et de coxibsInfo
- Publication number
- MA33742B1 MA33742B1 MA34859A MA34859A MA33742B1 MA 33742 B1 MA33742 B1 MA 33742B1 MA 34859 A MA34859 A MA 34859A MA 34859 A MA34859 A MA 34859A MA 33742 B1 MA33742 B1 MA 33742B1
- Authority
- MA
- Morocco
- Prior art keywords
- tramadol
- coxibs
- crystals
- crystal
- celecoxib
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 4
- 229960004380 tramadol Drugs 0.000 title abstract 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title abstract 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title abstract 2
- 229940111134 coxibs Drugs 0.000 title abstract 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- 229960000590 celecoxib Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention porte sur des co-cristaux de tramadol et d'agents de formation de co-cristaux choisis parmi les anti-inflammatoires non stéroïdiens (ains)/coxibs, sur leurs procédés de préparation et sur leurs utilisations comme médicaments ou dans des formulations pharmaceutiques, plus particulièrement pour le traitement de la douleur. Dans un mode de réalisation privilégié, le co-cristal est le (rac) - tramadol. Hci - célécoxib (1:1).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2009/007451 WO2010043412A1 (fr) | 2008-10-17 | 2009-10-16 | Co-cristaux de tramadol et d’ains |
PCT/EP2010/002385 WO2011044962A1 (fr) | 2009-10-16 | 2010-04-19 | Co-cristaux de tramadol et de coxibs |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33742B1 true MA33742B1 (fr) | 2012-11-01 |
Family
ID=42272447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34859A MA33742B1 (fr) | 2009-10-16 | 2012-05-11 | Co-cristaux de tramadol et de coxibs |
Country Status (20)
Country | Link |
---|---|
US (1) | US20230057884A1 (fr) |
JP (1) | JP5399564B2 (fr) |
KR (1) | KR101471585B1 (fr) |
CN (3) | CN104844513B (fr) |
AR (1) | AR079008A1 (fr) |
AU (1) | AU2010306168B2 (fr) |
BR (1) | BR112012005011B8 (fr) |
CA (1) | CA2771665C (fr) |
CO (1) | CO6511248A2 (fr) |
HK (1) | HK1173380A1 (fr) |
HR (1) | HRP20130316T1 (fr) |
IL (1) | IL218256A (fr) |
MA (1) | MA33742B1 (fr) |
MX (1) | MX2012003050A (fr) |
NZ (1) | NZ598353A (fr) |
PT (1) | PT2488169E (fr) |
SG (1) | SG178835A1 (fr) |
TW (1) | TWI441630B (fr) |
WO (1) | WO2011044962A1 (fr) |
ZA (1) | ZA201201892B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2177215A1 (fr) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-cristaux de tramadol et NSAID |
EP2311446A1 (fr) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprenant du Tramadol et du Célécoxib pour le traitement de la douleur |
MX2016006464A (es) * | 2016-05-18 | 2017-11-17 | Laboratorios Liomont S A De C V | Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor. |
CN107648228A (zh) * | 2017-10-24 | 2018-02-02 | 珠海赛隆药业股份有限公司 | 一种帕瑞昔布钠与盐酸曲马多组成的复合物及其用途 |
MX2018013070A (es) | 2017-12-29 | 2019-10-15 | Gruenenthal Gmbh | Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor. |
BR112021020893A2 (pt) | 2019-05-14 | 2022-04-19 | Esteve Pharmaceuticals Sa | Uso de cocristais de tramadol e celecoxib para o tratamento de dor, ao mesmo tempo que reduzindo a suscetibilidade a abuso do tramadol |
CN112007024A (zh) * | 2019-05-28 | 2020-12-01 | 江苏恒瑞医药股份有限公司 | 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661723B2 (en) * | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
WO2008085674A1 (fr) * | 2007-01-04 | 2008-07-17 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques comprenant des co-cristaux de célécoxib |
US20080031950A1 (en) * | 2007-04-27 | 2008-02-07 | Nectid Inc. | Novel anelgesic combination |
-
2010
- 2010-04-19 KR KR1020127008672A patent/KR101471585B1/ko active IP Right Grant
- 2010-04-19 MX MX2012003050A patent/MX2012003050A/es active IP Right Grant
- 2010-04-19 AU AU2010306168A patent/AU2010306168B2/en active Active
- 2010-04-19 BR BR112012005011A patent/BR112012005011B8/pt active IP Right Grant
- 2010-04-19 JP JP2012533490A patent/JP5399564B2/ja active Active
- 2010-04-19 NZ NZ598353A patent/NZ598353A/en unknown
- 2010-04-19 WO PCT/EP2010/002385 patent/WO2011044962A1/fr active Application Filing
- 2010-04-19 CN CN201510128805.9A patent/CN104844513B/zh active Active
- 2010-04-19 SG SG2012011672A patent/SG178835A1/en unknown
- 2010-04-19 CN CN201080046382.1A patent/CN102573825B/zh active Active
- 2010-04-19 PT PT107184723T patent/PT2488169E/pt unknown
- 2010-04-19 CN CN201510128029.2A patent/CN104817501B/zh active Active
- 2010-04-19 CA CA2771665A patent/CA2771665C/fr active Active
- 2010-10-14 TW TW099135028A patent/TWI441630B/zh active
- 2010-10-15 AR ARP100103777A patent/AR079008A1/es active IP Right Grant
-
2012
- 2012-02-22 IL IL218256A patent/IL218256A/en active IP Right Grant
- 2012-03-14 ZA ZA2012/01892A patent/ZA201201892B/en unknown
- 2012-03-16 CO CO12046131A patent/CO6511248A2/es not_active Application Discontinuation
- 2012-05-11 MA MA34859A patent/MA33742B1/fr unknown
-
2013
- 2013-01-17 HK HK13100720.2A patent/HK1173380A1/ unknown
- 2013-04-09 HR HRP20130316AT patent/HRP20130316T1/hr unknown
-
2022
- 2022-10-18 US US17/968,253 patent/US20230057884A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN104817501B (zh) | 2017-09-22 |
BR112012005011B1 (pt) | 2021-01-19 |
HK1173380A1 (en) | 2013-05-16 |
JP2013507402A (ja) | 2013-03-04 |
KR101471585B1 (ko) | 2014-12-10 |
IL218256A (en) | 2017-05-29 |
CN104844513B (zh) | 2018-08-07 |
ZA201201892B (en) | 2012-11-28 |
AU2010306168B2 (en) | 2014-10-30 |
CN104817501A (zh) | 2015-08-05 |
CN102573825B (zh) | 2015-04-22 |
NZ598353A (en) | 2014-01-31 |
AU2010306168A1 (en) | 2012-03-15 |
KR20120099212A (ko) | 2012-09-07 |
SG178835A1 (en) | 2012-05-30 |
CN104844513A (zh) | 2015-08-19 |
BR112012005011B8 (pt) | 2021-05-25 |
TW201116273A (en) | 2011-05-16 |
AR079008A1 (es) | 2011-12-21 |
CN102573825A (zh) | 2012-07-11 |
WO2011044962A1 (fr) | 2011-04-21 |
CO6511248A2 (es) | 2012-08-31 |
PT2488169E (pt) | 2013-04-03 |
US20230057884A1 (en) | 2023-02-23 |
BR112012005011A2 (pt) | 2016-05-03 |
HRP20130316T1 (en) | 2013-05-31 |
JP5399564B2 (ja) | 2014-01-29 |
CA2771665A1 (fr) | 2011-04-21 |
CA2771665C (fr) | 2015-10-06 |
IL218256A0 (en) | 2012-04-30 |
MX2012003050A (es) | 2012-05-29 |
TWI441630B (zh) | 2014-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33742B1 (fr) | Co-cristaux de tramadol et de coxibs | |
MA34474B1 (fr) | Agonistes de gpr40 | |
McCormack | Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis | |
NO20076508L (no) | Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav | |
MA33274B1 (fr) | Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale | |
MA32035B1 (fr) | Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4 | |
MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
MA35576B1 (fr) | Nouveaux composés | |
MA27668A1 (fr) | 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire | |
MA31845B1 (fr) | Pipéridino-dihydrothiénopyrimidines substituées | |
MA34727B1 (fr) | Imidazolylimidazoles condensés utilisés comme composés antiviraux | |
TN2009000138A1 (fr) | Biaryl-ether-urees | |
MA30325B1 (fr) | Composes qui potentialisent le recepteur ampa et leurs utilisations en medecine | |
MX336318B (es) | Co-cristales de tramadol y nsaids. | |
MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
MA31396B1 (fr) | Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes | |
FR2902007B1 (fr) | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques | |
MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
MA34227B1 (fr) | Procédé de préparation de compositions pharmaceutiques destinées à une administration orale, comprenant un ou plusieurs principes actifs, et compositions les comprenant | |
MA29723B1 (fr) | Composes | |
MA30916B1 (fr) | Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine |